Similar articles

• [A new NSAID selective COX-2 inhibitor].

  Ledro Cano D, Gómez Rodríguez B, Torres Domínguez Y, Hergueta Delgado P, Herrerías Esteban J, Herrerías Gutiérrez J. Ledro Cano D, et al. Rev Esp Enferm Dig. 1999 Aug;91(8):598. Rev Esp Enferm Dig. 1999. PMID: 10491496 Spanish. No abstract available.
• [Clinical pharmacology of selective inhibitors of cyclooxygenase-2].

  Patrignani P. Patrignani P. Acta Otorhinolaryngol Ital. 2003 Aug;23(4 Suppl 74):13-8, 37-40. Acta Otorhinolaryngol Ital. 2003. PMID: 15058604 Italian. No abstract available.
• [Selective cyclooxygenase-2 inhibitors and the digestive tract].

  Chaabouni H, Amouri A, Cheikh I, Kchaou M, Ouerghi H, Ben Mami N, Ben Ammar A. Chaabouni H, et al. Tunis Med. 2002 Aug;80(8):427-33. Tunis Med. 2002. PMID: 12703120 Review. French.
• The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).

  Wynn RL. Wynn RL. Gen Dent. 2000 Jan-Feb;48(1):16-20. Gen Dent. 2000. PMID: 11199547 No abstract available.
• COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.

  Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J. Ray WA, et al. Pharmacoepidemiol Drug Saf. 2003 Jan-Feb;12(1):67-70. doi: 10.1002/pds.798. Pharmacoepidemiol Drug Saf. 2003. PMID: 12616850 Review. No abstract available.